SUBJECT INDEX TO VOLUME 45

17β-estradiol, 1011
3-NT, 3-nitrotyrosine, 14
4-Aminopyridine, 649
5-HT, 72, 925
5-HT_{1A}, 1041
5-HT_{1A} receptor, 72, 925
5-HT_{2A}, 1041
[35S]GTPγS autoradiography, 145
(+)-202-791, 281

A

ACC, Anterior cingulate cortex, 220
Accessory β subunits, 814
Acetylcholine, 964
Acetylcholine release, 684, 1019
ACo, Cortical nucleus of the amygdala, 220
Action potential, 661
Acute tolerance, 82
AD, Alzheimer's disease, 14
Adenosine, 201, 575
Adenosine A_{2A}, 493
Adenosine A_{2A} receptor, 977
AEA, anandamide, 404
Agmatine, 534
AHi, Amygdalohippocampal area, 220
AI, Agranular insular cortex, 220
Alcohol deprivation effect, 325
Alcoholism, 122
Allodynia, 543
Allodynia (tactile pain), 96
Allopregnanolone, 461
Allosteric modulator, 293
Alzheimer's disease, 1, 14
Amitriptyline, 251
AMPA receptor, 738, 849, 1029
AMPA receptors, 325, 450
AMPA, α-amino-3-hydroxy-5-methylisoxazole-4-propionate, 703
AMPA, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid, 738
AMPA-R, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, 863
Amphiphysin, 787
Amygdala, 514
Amygdala-kindled seizures, 315
Anorectic response, 211
ANOVA, analysis of variance, 404
Anti-psychotic, 986
Antidepressant, 167, 251
Antiepileptic drug, 661
Antiepileptic drugs, 315
Antinociception, 82
Antipsychotic drug, 174, 1057
Antisense technology, 82
Anxiety, 231

Anxiolytic, 293
AO, Anterior olfactory nucleus, 220
AP-1, 251
AP-5, **d**(−)-2-amino-5-phosphonopentanoic acid, 703
Apomorphine, 182
Apoptosis, 182, 420, 623
AR-C compounds, 145
AR-JP, autosomal recessive juvenile Parkinson's, 1
AR-JP, autosomal recessive juvenille-onset form of Parkinson's disease, 14
Arc, Arcuate nucleus, 220
Atropine, 493
Attenuation, 167
Atypical antipsychotic, 190
Auditory system, 504
Autoinhibition, 925
Autoreceptor, 1101
AV, Anteroventral thalamic nucleus, 220
Aversion, 594
Axon growth, 995
A_1 receptors, 201
A_{2A} receptors, 201

B
Basal ganglia, 954, 1070
BDNF, 251
BDNF, brain-derived neurotrophic factor, 251
BDNF, brain-derived neurotrophin factor, 1130
Behavior, 242
Benzoyl pyrrole, 281
Bicuculline, 918
binding activity, 251
BMA, Basomedial amygdaloid nucleus, 220
BoNT/E, botulinum neurotoxin E, 857
BP 897, 174
Brain derived neurotrophic factor exon, 553
Brain expression, 585
Brain slices, 1041
Bupropion, 122

C
c-Fos, 473, 594
c-fos mRNA, 190
Caffeine, 977
Calcineurin, 394, 703
Calcium/calmodulin, 260
Calcium/calmodulin kinase II, 986
Cannabinoid receptor, 594
Cannabinoid $_2$ receptor, 404
CASK, Calcium/calmodulin-dependent serine protein kinase, 1
Caspase, 394
Caspase-3, 672
Catechol-*O*-methyltransferase, 1011
Catecholamine, 1070
Caudate-putamen, 493
CAZ, ceftazidime, 304

Ca^{2+} channel current, 429
Ca^{2+} channels, 814
Ca^{2+}-dependent K^+ channel, 714
CB, cannabinoid, 404
CB_1, cannabinoid $_1$ receptor, 404
CB_2, cannabinoid $_2$ receptor, 404
CDCRel1, cell division control related protein, 1
Ce, Central amygdaloid nucleus, 220
Central leptin gene delivery, 211
Central nervous system neurons, 623
Central nucleus of amygdala, 473
Cephalosporin, 304
Ceramide, 1130
Cerebellar granule neurons, 672
Cerebellum, 863
Cerebrocortical slices, 201
CEZ, cefazolin, 304
CFPM, cefepime, 304
CFSL, cefoselis, 304
CG, Central gray, 220
cGMP, 1041
Chick, 355
Chicken α4β2 nicotinic receptor, 133
Chicken α7 nicotinic receptor, 133
Chlorimipramine, 935
CHO-K1 cell line, 182
Cholinergic, 1111
Cholinergic interneuron, 45
Cholinergic neurons, 1019
Cisplatin, 380
Cl, Claustrum, 220
Clathrin, 787
CM, Central medial thalamic nucleus, 220
CNQX, 6-cyano-7-nitroquinoxaline-2,3-dione, 703
Cocaine, 106
Compensatory events, 1080
Conditioned place preference, 106
Contraction, 1019
Convulsions, 304
Corticosteroids, 925
CPR, cefpirome, 304
CREB, cAMP response element-binding protein, 251
Cross-sensitization, 106
ct, carboxy terminus, 1
CTM, cefotiam, 304
Cyclic AMP, 575, 885
Cyclic GMP, 1151
Cyclin-dependent kinases, 672
Cyclosporin A, 703
CYP2B6, 122
CZOP, cefozopran, 304
C. *elegans*, 768

D

D2 dopamine receptor, 814
DA, dopamine, 703

DA, dopamine or Dopaminergic, 14
DAG-kinase, diacylglycerol kinase, 1130
Daidzein, 270
DAMGO, [D-Ala2, N-MePhe4,Gly-ol5]-enkephalin, 82
DAQ, DA-quinone, 14
DARPP-32, 703
DAT, dopamine transporter, 1
DAT, plasma membrane dopamine transporter, 14
Declustering, 863
Delayed rectifier current, 661
Dentate granule cell, 116
Dentate gyrus, 251
Depression, 231, 251, 925, 935
Desipramine, 553
Development, 439
DG, Dentate gyrus, 220
DHCer, dihydroceramide, 1130
DI, Dysgranular insular cortex, 220
Dicarboxyphenylglycine, 473
Discriminated avoidance learning, 355
Dizocilpine, 174
DLB, dementia with Lewy Bodies, 14
DLG, Dorsal lateral geniculate nucleus, 220
DMS, *N,N'*-dimethyl sphingosine, 1130
Dopamine, 954, 1011
Dopamine receptors, 1057
Dopamine release, 484, 945
Dopaminergic neurons, 334
Dopaminergic supersensitivity, 986
Dorsal horn, 1101
Dorsal raphe nucleus, 72, 925
DPDPE, [D-Pen2,5]-enkephalin, 82
DRG, dorsal root ganglion, 404
Drosophila ALS chicken β2 hybrid nicotinic receptor, 133
Drosophila SAD chicken β2 hybrid nicotinic receptor, 133
Drug metabolism, 122
dSlo, 714
DTG, 945
DTT, dithiothreitol, 738
Duloxetine, 935
Dynamin, 787
Dyskinesias, 954
D_3 receptor-deficient mice, 174

E

E-6375 (4-butoxy-2-[4-(2-cyanobenzoyl)-1-piperazinyl] pyrimidine hydrochloride), 1029
Electrical nerve stimulation, 1111
Electroconvulsive seizure, 553
Electrophysiology, 72, 925, 1093
ELISA, enzyme-linked immunosorbent assay, 251
EMSA, Electrophoretic mobility shift assay, 251
En, Endopiriform nucleus, 220
Enantiomer, 167
Endocytosis, 787, 797
Endoplasmic reticulum (ER), 768

ENT, Entorhinal cortex, 220
Entorhinal cortex, 190, 907
Epilepsy, 649, 661
EPSC, excitatory postsynaptic current, 863
EPSC, excitatory postsynaptic potential, 738
ER retention, 755
ERK, 863
Escitalopram, 167
Estrogen receptor, 1011
Estrogen response element, 1011
Ethanol, 977
Ethanol self-administration, 325
Ethanol sensitivity, 325
Ethanol tolerance, 325
Ethanol withdrawal seizures, 429
Etifoxine, 293
Etomidate, 57, 315
Excitatory amino acid transporter, 885
Excitotoxicity, 895
Exocytosis, 777, 797
Extrapyramidal side-effects, 1057

F

FB1, fumonisin B1, 1130
Fencamfamine, 1151
Fetus, 461
Firing frequency, 334
FK506, 394
Flavopiridol, 672
FLIPR, 334
Fluorescence imaging, 797
Fluoxetine, 553
FM1-43, 797
Formalin test, 594
FP, fluorescence polarization, 738
fPD, familial PD, 14
FPL 64176, 281
Fr, Frontal cortex, 220
Frontal cortex, 251, 1041
Fusion, 797

G

G-protein, heterotrimeric guanine nucleotide-binding regulatory protein, 82
G-proteins, 82, 814
GABA, 304
GABA release, 575, 907
GABA, gamma-amino butyric acid, 304
GABAergic inhibitory synaptic transmission, 57
$GABA_A$ receptor, 57, 293, 1029
$GABA_A$ receptors, 873
$GABA_A$, γ-aminobutyric acid A, 270
GAP, GTPase-activating protein, 82
Gastric fundus, 684
Gbeta5 proteins, 82
GCI, glial cytoplasmic inclusion, 14

General anaesthesia, 57
General anaesthetic, 1029
Gerbil, 242
GGL, G-protein γ-subunit-like, 82
GI, Granular insular cortex, 220
GIRK, 925
Glial cells, 637
Glucocorticoids, 925
GluR, glutamate receptor, 863
GluR1, 325
Glutamate, 649, 837, 849, 1120, 1151
Glutamate receptor, 738, 768, 863
Glutamate receptors, 755
Glutamate release, 201, 907
Glycine, 585
Glycogen synthase kinase-3, 623
GPCR, G-protein coupled receptor, 82
GRIP, glutamate receptor interacting protein, 1
GTPase activity, 814
Guinea pig, 380, 661
Guinea-pig, 1019
G_i-linked P2Y receptors, 145

H

Heat shock protein, 649
HECT, homology to E6-AP carboxy terminus, 1
Hemokinin, 242
HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 304
HIP, Hippocampus, 220
Hippocampus, 116, 251, 649, 797, 857, 885
HL, Hindlimb area, 220
HRP, horse radish peroxidase, 863
Human brain, 122
Human tissue, 116
Hyperalgesia, 543
Hyperthermia, 484
Hypothalamic-pituitary-adrenal, 605
Hypothalamo–pituitary–adrenal, 925

I

IAM, Interanteromedial thalamic nucleus, 220
IBR, in-between RING domain, 1
IL-1, interleukin-1, 14
Ileum, 1019
In vivo microdialysis, 514
Inferior colliculus, 429
Inflammation, 605, 1111
Inhibitory synaptic transmission, 1029
iNOS mRNA, 260
Inositol phosphates, 691, 885
Insertion of new AMPA receptors, 439
Interaction, 954
Intracellular zinc, 420
Intrathecal, 96
Iontophoresis, 368

IPSCs, 116
Ischemia, 201, 637
I_{Gly}, glycine-induced current, 270

K
K252a, 995
KA, kainate, 703
Ketamine, 315
Kiss-and-run, 797
KLH, keyhole limped hemocyanin, 738
Knockout, 977
Knockout mice, 96

L
L-DOPA, 524
L-type Ca^{2+} channels, 281
LA, Lateral amygdaloid nucleus, 220
Lateral septum, 190
Lck, 720
LD, Laterodorsal thalamic nucleus, 220
Leptin signal transduction, 211
Lewy bodies, 14
Ligand binding site, 768
Limbic system, 918
Liposomal delivery, 691
LO, Lateral orbital cortex, 220
Locomotor activity, 565
LP, Lateral posterior thalamic nucleus, 220
LPS, 1120
LS, Lateral septal nucleus, 220
LTD, 450, 863
LTP, 439, 450
LY341495, 565
LY366457, 565
Lyn, 720

M
M1 mAChR, 260
m1 Receptor mRNA, 260
M3 receptors, 504
MAO, 524
MAPK, 863
MAPK, mitogen activated protein kinase, 14
MBS, *m*-maleimidobenzoic acid *N*-hydroxysuccinimideester, 738
Medial prefrontal cortex, 72
Median raphe nucleus, 72
MEK, 863
Melanocortin pathway, 211
Membrane potential, 368
Memory consolidation, 355
Metabotropic glutamate receptor, 473, 885
Metabotropic glutamate receptors, 45, 155, 565, 895
Metabotropic receptor 5, 484
Methamphetamine-induced toxicity, 484
MG, Medial geniculate nucleus, 220

mGlu8 receptor, 473
mGluR antagonist, 565
Mice, 345, 977
Microdialysis, 524, 945, 1050
Midbrain slice, 504
Milnacipran, 935
Mint, 837
MM, Medial mammillary nucleus, 220
Morphine, 368, 543
Morphine withdrawal, 575
Mouse, 242, 1050
Mouse brain, 82
MPS, multiple peptide synthesis, 738
MPTP toxicity, 155
MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 14
MR200, 945
MS, Medial septal nucleus, 220
MSA, multiple system atrophy, 14
Muscarinic, 1111
Muscle rigidity, 1057

N
N-type Ca^{2+} channels, 281
Na,K-ATPase, 1151
NAc, Nucleus accumbens, 220
NACP, non-amyloid component of plaque, 14
Nafadotride, 174
NBIA-1, neurodegeneration with brain iron accumulation type-1, 14
Neonicotinoids, 133
Neostriatum, 986
Nerve growth factor, 543
Neurodegeneration, 1, 14, 649
Neuroinflammation, 1120
Neuroleptic, 986
Neuronal apoptosis, 995
Neuronal firing, 334, 1070
Neuronal survival, 995
Neuropathic pain, 543
Neuroprotection, 155, 420, 484, 623, 637, 672, 895
Neurosteroid, 461, 873
Neurotransmission, 857
Neurotrophin, 553
Neurotrophins, 1130
NF-κB, 1120
NGF, 995
NGF, nerve growth factor, 1130
Nicotine, 122, 345, 514
Nicotinic acetylcholine receptor, 133, 345
Nicotinic receptor, 964
Nifedipine, 703
Nitric oxide, 412, 1120
Nitric oxide synthase, 1151
NK_1 receptor, 231
NMDA, 304, 637, 703, 1041
NMDA receptor, 738, 1029

NMDA receptors, 450
NMDA, *N*-methyl-**d**-aspartate, 304, 738
nNOS mRNA, 260
Nociceptin, 220
Nociception, 220, 605
NOE, *N*-oleoyl-ethanolamine, 1130
Non-competitive inhibition, 585
Non-receptor protein tyrosine kinase, 720
Non-steroidal anti-inflammatory drugs, 412
Noncompetitive inhibitor, 964
Noradrenaline, 355, 524, 1070
Norepinephrine, 514, 935
NSF, *N*-ethylmaleimide sensitive factor, 857
Nucleus accumbens, 190, 703
Nucleus raphe magnus, 612
Nucleus reticularis gigantocellularis, 612
N-methyl-**d**-aspartate, 1120

O

ODN, antisense oligodeoxynucleotide, 82
Open channel block, 270
Opioid receptor, 220
Opioid receptors, 82
Opioids, 954
Organ of Corti, 380
Orphanin FQ, 220, 612
Ototoxicity, 380
Ovine, 461
Oxygen consumption, 211

P

$p75^{NTR}$, p75 neurotrophin receptor, 1130
Pael-R, parkin-associated endothelin receptor-like, 1
PAG, periaqueductal grey matter, 82
738, 863, polyacrylamide gel electrophoresis, 738, 863
Pain, 412, 594, 1111
Pain modulation, 612
Panic, 594
Par-4, 672
Parkin, 1
Parkinson, 493, 954
Parkinson's disease, 1, 14, 45, 155, 1011
Partial agonist, 334
PaS, Parasubiculum, 220
PAULs, parkin/ariadne like ubiquitin ligases, 1
PBS, phosphate-buffered saline, 863
PC, Paracentral thalamic nucleus, 220
PC12 cells, 281, 777
PD, Parkinson's disease, 1, 14
PD98059, 2′-amino-3′-methoxyflavone, 863
PDAc, phorbol-12,13-diacetate, 857
PDZ, 1
PDZ domains, 738
PDZ, PSD-95/discs large/ZO-1 homologous domain, 1

Pentylenetetrazol, 918
Pentylenetetrazole, 534
Peptides, 1101
Periaqueductal Gray, 575
Periaqueductal gray, 612
Periaqueductal grey, 594
Peripheral anti-nociception, 404
Permeation, 768
PF, Parafascicular thalamic nucleus, 220
PHF, paired helical filaments, 14
Phorbol ester, 857
Phosphatidylinositol 3-kinase, 623, 691
Phospholipase C, 260
Phosphorylation, 755, 857, 873
PI3-kinase, phosphatidyl inositol 3-kinase, 1130
PICK1, protein interacting with C-kinase, 1
Picrotoxin, 270, 918
Pig, 684
PIR, Piriform cortex, 220
PKA, 755, 1151
PKA, cyclic AMP dependent kinase, 270
PKC, 755, 863
PKC, protein kinase C, 14, 270, 857, 863
Plasma extravasation, 1101
Plasticity, 837
Platelet P2Y12 receptor antagonists, 145
PLD2, phospholipase D2, 14
Po, Posterior thalamic nuclear group, 220
Polymorphism, 345
Positive modulation, 895
Post-ganglionic sympathetic neuron, 605
Postsynaptic, 1050
Postsynaptic currents, 504
Postsynaptic density, 738
Postsynaptic density-95, 720
Postsynaptically silent synapses, 439
PP, protein phosphatase, 863
PP1, protein phosphatase 1, 703
PPMP, **dl**-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol, 1130
Presynaptic, 1050
Presynaptic P2Y receptors, 145
Presynaptically silent synapses, 439
PRh, Perirhinal cortex, 220
Probability of glutamate release, 439
Propofol, 315
Prostanoid EP3 receptor, 96
Prostanoid receptors, 684
Protein kinase C, 260
Protein-protein interactions, 1
Protein–protein interaction, 714
PrS, Presubiculum, 220
PSD-95, 738
Psychostimulants, 106
PTK, tyrosine kinase, 270
PV, Paraventricular thalamic nucleus, 220

pyrithione, 1-hydroxypyridine-2-thione, 420

Q

Quantal transmitter release, 691

R

R-citalopram, 167
R7, subfamily of RGS proteins, including RGS6, RGS7, RGS9 and RGS11, 82
Rasagiline, 524
Rat, 231, 404, 484, 585, 661, 1093
Rat midbrain slice, 334
Rebound current, 270
Receptors, 304
Reinforcement, 355
Respiratory depression, 368
Respiratory neuron, 368
Retinal cells, 1080
Retinal ganglion cells, 637
Retrograde survival, 1130
RGS proteins, 82
RGS, regulator of G-protein signaling, 82
ROS, reactive oxygen species, 14
Rt, Reticular thalamic nucleus, 220
RXR, 755

S

S, Subiculum, 220
S1P, sphingosine 1-phosphate, 1130
SA, SNAP-25 with Ser187Ala mutation, 857
SAP102, 738
SAP97, 738
SC, Superior colliculus, 220
SCH 58261, DPCPX, Righting reflex, 977
SCh, Suprachiasmatic nucleus, 220
SDS, sodium dodecyl sulfate, 863
SDS, sodium dodecylsulphate, 738
SE, SNAP-25 with Ser187Glu mutation, 857
Self-administration, 514
Sensory neurones, 1101
Serotonin, 925, 935
Serotonin receptors, 1050, 1057
Serotonin reuptake inhibition, 167
SG, Supragenículate thalamic nucleus, 220
SH-SY5Y, 394
Signaling endosome, 995
Single motor unit, 412
Skin, 1101
Slob, 714
SM proteins, 777
SM, sphingomyelin, 1130
Smoking, 122
Smooth muscle cells, 684
SNAP-25, 857
SNARE, 777
SNARE, soluble NSF attachment protein receptor, 857

SO, Supraoptic nucleus, 220
Sodium thiosulfate, 380
Somatostatin levels, 1080
Somatostatin receptor 1 null mutation, 1080
Somatostatin receptor 2 expression, 1080
Spinal cord, 412, 543, 1093, 1111
Src, 720
Stargazin: PD2 domain, 849
Stress-induced ethanol drinking, 325
Striatum, 45, 493, 945
Strychnine, 918
Substance P, 242, 1093
Subthalamic nucleus, 1070
SuG, Superficial gray layer of the superior colliculus, 220
SuM, Supramammillary nucleus, 220
Superior cervical ganglion, 281
Superior colliculus, 473
Swt, SNAP-25 with wild-type Ser187, 857
Sympathetic neurons, 1130
Sympathoadrenal, 605
Synapse, 837
Synaptic development, 504
Synaptic plasticity, 450, 849
Synaptic vesicle, 691, 797
Syntaxin, 777
S-adenosyl-l-methionine, 1011

T

Tachykinin, 242
Tachyphylaxis, 82
Tardive dyskinesia, 986
TBPS, 461
TC-2559, 334
Te, Temporal cortex, 220
Tert-butylbicyclophosothionate, 461
TH, tyrosine hydroxylase, 14
Thapsigargin, 394
TNFα, tumor necrosis factor α, 14
Tonically active neurons, 45
Toxicity, 420
TPA, tetradecanoylphorbol 13-acetate, 863
TPEN, N, N, N', N', tetrakis (2-pyridylmethyl) etylenediaminepentaethylene, 420
Trafficking, 755, 768
Transcription factor, 251
Transporter, 585
Transporters, 935
Tranylcypromine, 553
Tricaine, 3-aminobenzoic acid ethyl ester, 304
Tricyclic antidepressant, 964
Trihexyphenidyl, 493
TrkA, 995
TrkA, tyrosine kinase receptor A, 14
TT, Tenia tecta, 220
Tu, Olfactory tubercle, 220
TWEEN, polyoxyethylenesorbitan monooleate, 404
Typical antipsychotic, 190

Tyrosine kinase antagonists, 270

U

U0126, 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio) butadiene., 863
Ub, ubiquitin, 1, 14
UbcH7/8, 1
Ubiquitination, 1
UCH-L1, ubiqutin carboxyl-terminal hydrolase, 1
ULD, ubiquitin like domain, 1
UPS, ubiquitin-proteosome system, 1
Uptake, 585
Urotensin II, 1019

V

Valproate, 907
Vas deferens, 524
Veh, vehicle, 404
Venlafaxine, 935
Ventral tegmental area (VTA), 334
VL, Ventrolateral thalamic nucleus, 220
VLG, Ventral lateral geniculate nucleus, 220
VLO, Ventral lateral orbital cortex, 220
VMH, Ventromedial hypothalamic nucleus, 220
Voltage clamp, 334
VR1, vanilloid receptor subtype 1, 404
VTA, ventral tegmental area, 270

W

WAY100635, 1050
WDR neurons of the spinal dorsal horn, 612
White matter tracts, 145
Whole-cell patch clamp, 270
Whole-cell patch-clamp, 504
Wind-up, 412, 1093
Withdrawal, 106

X

X11, 837
Xenopus oocyte, 334
Xenopus oocyte, 293
Xenopus oocytes, 814

Y

Yes, 720
Yohimbine, 534

Z

Zinc, 637
α-Synuclein, 14
α-Synucleinopathies, 14
αSN, alpha-synuclein, 14
α4β2 nicotinic receptors, 334
α_1-adrenoceptor, 1070
α_2-Adrenergic, 534
α_2-adrenoceptors, 355
β Subunit, 293
β-Amyloid, 623

β-amyloid toxicity, 895
μ Receptor mechanism, 368
μ-receptor coupling, 575
σ Receptors, 945
τ_d, time constant of decay, 270
τ_{off}, deactivation time constant, 270
τ_{on}, activation time constant, 270
l-Arginine, 534
l-NAME, 534
κ-Opioid receptor, 96

AUTHOR INDEX TO VOLUME 45

Aceves, J., 1070
Achat-Mendes, C., 106
Ago, Y., 1050
Akamatsu, M., 133
Alfonso Romero-Sandoval, E., 412
Allen, P., 703
Alvarez-Cervera, F.J., 493
Anderson, K.L., 106
Arankowsky-Sandoval, G., 493
Araújo, A.P.N., 1151
Aravanis, A.M., 797
Arcos, D., 1070
Arias-Montaño, J.-A., 1070
Arias, H.R., 964
Avellar, M.C.W., 1120
Ayala, G.X., 649

Baba, A., 1050
Backus, K.H., 504
Baez, M., 473
Bagnoli, P., 1080
Banerjee, S.B., 553
Barbieri, S., 14
Barrett, C.F., 281
Bartoszyk, G.D., 1057
Battaglia, G., 155
Battaglia, G., 895
Beart, P.M., 461
Beckett, S.R.G., 594
Belelli, D., 57
Belelli, D., 1029
Benedetti, G., 334
Benowitz, N., 605
Bentley, G., 231
Bergeron, M., 473
Bernardi, G., 45
Berra, A., 260
Bédard, P.J., 954
Biagioni, F., 155
Blanpied, T.A., 755
Boerrigter, P., 661
Bonfanti, A., 201
Bonsi, P., 45
Borda, E., 260
Borowicz, K.K., 315
Bortolotto, Z.A., 828
Bouzat, C., 964
Brailoiu, E., 691
Brain, S.D., 1101
Bravo, R., 672
Bredt, D.S., 849
Broad, L.M., 334
Bruna, A., 672
Bruno, V., 155
Bruno, V., 895
Buchman, V.L., 14
Bureau, Y., 918
Busceti, C.L., 155
Bymaster, F.P., 935

Caelles, C., 672
Cagnotto, A., 945
Cahill, C.M., 543
Calabresi, P., 45
Callachan, H., 57
Callachan, H., 1029
Camarasa, J., 672
Camins, A., 672
Campenot, R.B., 995
Cantí, C., 814
Canudas, A.M., 672
Canzoniero, L.M.T., 420
Carlson, E.J., 231
Cascieri, M.A., 231
Casula, A., 57
Centonze, D., 45
Cervia, D., 1080
Chapman, V., 404, 594
Chaudhary, A., 585
Chen, H.-X., 116
Chen, X., 777
Chen, Y., 334, 738
Cherubini, E., 439
Chicchi, G.G., 231
Chidlow, G., 637
Childers, S.R., 220
Choi, D.W., 420
Christie, M.D.J., 575
Coderre, T.J., 543
Cohen-Williams, M.E., 242
Collingridge, G.L., 828
Conn, P.J., 585
Conway, M.W., 565
Corsini, G.U., 182
Costentin, J., 977
Coutureau, E., 190
Cowen, M.S., 325
Crossley, K.J., 461
Cunningham, M.O., 907
Czuczwar, S.J., 315

Dakoji, S., 849
Daniell, L., 787
Dayan, L., 524
De Backer, O., 684
De Camilli, P., 787
De Deurwaerdère, P., 945
Dehpour, A.R., 534
Del Soldato, P., 412
DeLucia, R., 1151
Demehri, S., 534
Dev, K.K., 1, 14
Di Salvo, J., 231
Di Scala, G., 190
Dias, B.G., 553
Dickenson, A.H., 1093
Dolphin, A.C., 814
Dragic, Z., 895
Dray, A., 543
Duffy, R.A., 242
Duman, R.S., 553
Dun, N.J., 691
Dunlop, J.I., 1029

Ehlers, M.D., 755
El Yacoubi, M., 977
Elmes, S.J.R., 404
Endo, S., 863
Epelbaum, J., 1080
Escubedo, E., 672
Evans, D.C., 935

Facci, L., 623
Fairchild, G., 925
Farsad, K., 787
Fei, H., 714
Fetoni, A., 380
Fienberg, A.A., 703
Finberg, J.P.M., 524
Finley, M.F.A., 857
Finn, D.P., 594
Flanagin, B.A., 345
Flor, P.J., 895
Flores, G., 1070
Fornai, F., 155
Foster, A.C., 885
Franceschini, D., 623
Frenguelli, B.G., 873
Fu, Y., 514

Galdi, S., 703
Galimberti, S., 182
Ganzinelli, S., 260

Gao, Y.-J., 612
Gartside, S.E., 72
Garzón, J., 82
Gasparini, F., 895
Gass, P., 325
Gemmell, D.K., 57
Gentet, L.J., 57
Georg Margineanu, D., 661
Gerard, N.P., 1101
Gibbs, M.E., 355
Gillardin, J.-M., 293
Glezer, I., 1120, 1151
Gonzalez, P.K., 281
Gorji, A., 661
Gould, S.L., 231
Góngora-Alfaro, J.L., 493
Gołembiowska, K., 484
Grant, A.D., 1101
Green, P., 605
Greengard, P., 703
Grégoire, L., 954
Grouselle, D., 1080
Grunwald, M.E., 768
Gu, J.G., 116
Gubellini, P., 45
Guitart, X., 1029
Guitton, M.J., 380
Gumilar, F., 964
Gustafson, E., 242
Gutierrez, B., 1029

Hack, S.P., 575
Haji, A., 368
Hajós, M., 72
Hamilton, N.M., 57
Hamon, A., 293
Harata, N.C., 797
Harney, S.C., 873
Hashimoto, K., 251
Hatano, K., 304
Hauke, V., 787
Hedrick, J.A., 242
Hell, J.W., 738
Hemrick-Luecke, S.K., 935
Herbeaux, K., 190
Heredia-López, F., 493
Heron-Maxwell, C., 565
Herrero, J.F., 412
Hill, A., 231
Hirabayashi, T., 1019
Hirst, J.J., 461
Ho, S.L., 1011
Hofele, K., 14
Homayoun, H., 534
Honar, H., 534
Horie, S., 1019
Hoyer, D., 1080
Hue, B., 293
Huganir, R.L., 837
Hunt, S.P., 1093

Ichikawa, A., 96
Ihara, M., 133
Ikeda, F., 304
Inderbitzin, W., 895
Ingram, C.D., 925
Isaac, J.T.R., 450
Ito, S., 96
Itzhak, Y., 106
Iyo, M., 251

Jacobson, M., 585
Jhaveri, M.D., 594
Jiang, H., 1011
Jiang, Z.L., 270
Jiménez, A., 672
Jones, R.S.G., 907
Jorda, E.G., 672

Kalia, L.V., 720
Kane, V.B., 514
Kaplan, J.M., 768
Karimzadegan, S., 849
Kawamoto, E.M., 1120, 1151
Keipert, C., 504
Kendall, D.A., 404, 594
Kilburn, R., 231
Kim, H., 345
Kita, Y., 394
Klitgaard, H., 661
Kobayashi, T., 96
Koch, S., 935
Komai, K., 133
Konieczny, J., 484
Koyama, Y., 1050
Kreienkamp, H.-J., 1080
Kreilgaard, M., 167
Krnjević, K., 270
Kuhn, R., 895
Kumakiri, C., 251
Kurtz, M.M., 231
Kuwamura, M., 133

Lachowicz, J.E., 242
Laitinen, J.T., 145
Lambert, J.J., 57, 873
Lambert, J.J., 1029
Lau, Y.-S., 986
Launey, T., 863
Laverty, M., 242
Lavezzari, G., 729
Lawrence, A.J., 461
Leclere, P.G., 684
Ledent, C., 977
Lee, R., 729
Lefebvre, R.A., 684
Leitch, M.M., 925
Lepscha, L.B., 1151
Leriche, L., 174
Lerman, C., 122
Lever, I.J., 1101
Levine, J.D., 605
Levitan, I.B., 714
Lim, I.A., 738
Linden, A.-M., 473
Liu, L., 281
Lloyd Faulconbridge, R.V., 380
Lorenc-Koci, E., 1057
López-Fando, A., 82

Mabuchi, T., 96
Macdonald, R.L., 345
MacInnis, B.L., 995
Madau, P., 57
Madeja, M., 661
Madison, D.V., 857
Maguire, M., 242
Maj, M., 895
Majchrzak, M., 190
Malcangio, M., 1101
Mallorga, P.J., 585
Manzerra, P., 420
Marcoli, M., 201
Marcourakis, T., 1120
Marques, R., 585
Marrazzo, A., 945
Marsden, C.A., 594
Mash, D.C., 122
Mashimo, T., 304
Matheny, M., 211
Matos, M.F., 777
Matsuda, K., 133
Matsuda, T., 1050
Matsumura, S., 96
Matsuoka, N., 304
Matta, S.G., 514
Matthews, P., 828
Maura, G., 201
McCallum, J., 729
McIntyre, D.C., 918
Mennini, T., 945
Meredith, G.E., 986
Merrill, M.A., 738
Merrywest, S.D., 57
Miao, F.J.-P., 605

Miksys, S., 122
Mills, S.G., 231
Minami, T., 96
Miyamoto, M.D., 691
Mochizuki, Y., 304
Moison, D., 945
Monn, J.A., 565
Monopoli, A., 201
Monte, M.D., 1080
Moo-Puc, R.E., 493
Morad, M., 429
Morel, A., 293
Morgan, C.A., 242
Mukherjee, K., 777
Munhoz, C.D., 1120, 1151
Muntoni, A.-L., 57
Muramoto, M., 394
Murayama, T., 1019
Mørk, A., 167

Naeve, G.S., 885
Nairn, A.C., 703
Nakamichi, N., 637
Nakatsuka, T., 116
Narumiya, S., 96
Nelson, D.L., 935
Nicoletti, F., 155
Nicoletti, F., 895
Nicoll, R.A., 849
Nishimura, S., 394
Nitsos, I., 461
Nomura, Y., 1019
Nuñez, A., 1070
N'Gouemo, P., 429

Ochoa, G., 787
Ohi, Y., 368
Okamoto, H., 251
Okazaki, M., 368
Okuma, Y., 1019
Ongini, E., 201
Ornstein, P., 565
Osborne, N.N., 637
Ossowska, K., 484
Otake, M., 133
O'Neill, M.F., 565

Pallàs, M., 672
Pangallo, M., 623
Paparelli, A., 155
Pardini, C., 182
Parmentier, M., 977
Pau, D., 1029
Peden, D.R., 1029
Perry, K.W., 935
Peters, J.A., 57
Peters, J.A., 1029
Petroske, E., 986
Petrucci, C., 1080
Pettibone, D.J., 585
Pezet, S., 1101
Phillips, K.G., 334
Pineda, J.C., 493
Pisani, A., 45
Planeta, C.S., 1151
Pontarelli, F., 155
Posse de Chaves, E.I., 1130
Prezzavento, O., 945
Pubill, D., 672
Puel, J.L., 380
Pujol, R., 380
Pyle, J.L., 797

Qin, C., 345

Rabin, R.A., 1041
Racine, R.J., 918
Radhakrishnan, R., 1111
Raiteri, L., 201
Raiteri, M., 201
Ramsden, D.B., 1011
Randolph, G., 242
Raymond, V., 133
Regina, M.J., 1041
Riazi, K., 534
Richter, D., 1080
Rittenhouse, A.R., 281
Rizo, J., 777
Roberts, D., 828
Roche, K.W., 729
Rodríguez-Díaz, M., 82
Rodríguez-Muñoz, M., 82
Roe, C.H., 594
Ronsisvalle, G., 945
Roper, S.N., 116
Roushanzamir, F., 534
Rovelli, G., 1
Ruggieri, S., 155
Rupniak, N.M.J., 231

Saito, T., 1019
Salter, M.W., 720
Samadi, P., 954
Sattelle, D.B., 133
Sánchez-Blázquez, P., 82
Sánchez, C., 167
Scarpace, P.J., 211
Scavone, C., 1120, 1151
Scheller, R.H., 857
Schoepp, D.D., 473
Schroff, K.-C., 325
Schwartz, J.-C., 174
Scott, D.B., 755
Seillier, A., 190
Selkirk, J.V., 885
Senger, D.L., 995
Shan, L.-S., 242
Sharp, B.M., 514
Sharp, T., 72
Sharples, T.J.W., 334
Sheline, C.T., 420
Shepheard, S., 231
Sher, E., 334
Shields, P.G., 122
Shimizu, E., 251
Shimomura, M., 133
Shino, Y., 251
Shirasawa, H., 251
Siep, E., 661
Sierra, A., 1070
Sillar, K.T., 57
Sim-Selley, L.J., 220
Skaper, S.D., 623
Slepnev, V., 787
Sluka, K.A., 1111
Snyder, G.L., 703
Sokal, D.M., 404
Sokoloff, P., 174
Someya, A., 1019
Sommer, B., 1
Song, M.-S., 1130
Spampinato, U., 945
Spanagel, R., 325
Speckmann, E.-J., 661
Spitzmaul, G., 964
Sprengel, R., 325
Stein, T., 895
Steingart, M., 918
Sterin-Borda, L., 260
Stevens, D.A., 623
Stitzel, J.A., 345
Stoehr, N., 895
Stricker, N.L., 837
Strijbos, P.J.L.M., 623
Sugimoto, M., 304
Sugimoto, Y., 96
Summers, R.J., 355
Sur, C., 585
Suzuki, R., 1093
Südhof, T.C., 777
Swain, C., 231

Takeda, R., 368
Tapia, R., 649
Terai, T., 304

Thiriet, N., 190
Thompson, L.K., 935
Threlkeld, P.G., 935
Tomita, S., 849
Tsao, K.-L., 231
Tsien, R.W., 797
Tsurumaki, Y., 1019
Tümer, N., 211
Tyndale, R.F., 122

Uchida, I., 304
Uri, A., 145
Ushikubi, F., 96

Vafaie, K., 534
Vaglini, F., 182
Vaidya, V.A., 553
van der Putten, H., 1, 14
Varga, V., 72
Varty, G.B., 242
Vasilaki, A., 1080
Vasiljev, K.S., 145
Vassileva, G., 242
Vaugeois, J.-M., 977
Vaughan, C.W., 575
Verdaguer, E., 672
Verleye, M., 293
Vogt, B.A., 220
Vogt, L.J., 220
Voronin, L.L., 439
Vranesic, I., 895

Walker, D.W., 461
Wang, F.S., 270
Wang, J., 380
Wang, J.Q., 986
Wardas, J., 1057
Wikström, M.A., 828
Will, B., 190
Williams, A.R., 231
Williams, J.B., 585
Winter, J.C., 1041
Wolfarth, S., 484, 1057
Woodhall, G.L., 907
Wu, G.-C., 612

Xie, T., 1011

Yamamoto, R., 895
Yamazaki, H., 368
Yamazaki, S., 304
Yamazaki, T., 394
Yang, Z.-L., 612
Yasuda, S., 1019
Ye, J.H., 270
Yigit, M., 504

Zhang, Y., 211
Zhang, Y.-Q., 612
Zhou, Y., 714
Zhu, L., 270
Zolotukhin, S., 211
Zwart, R., 334
Zwiller, J., 190